EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY 4.0

Brand-specific estimates of influenza vaccine effectiveness for the 2021–2022 season in Europe: results from the DRIVE multi-stakeholder study platform

Anke L Stuurman, Antonio Carmona, Jorne Biccler, Alexandre Descamps, Miriam Levi, Ulrike Baum, Ainara Mira-Iglesias, Stefania Bellino, Uy Hoang, Simon de Lusignan, Roberto Bonaiuti, Bruno Lina und 4 weitere

Frontiers in Public Health · 2023

DOI: 10.3389/fpubh.2023.1195409 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Frontiers in Public Health, 2023. Verfasst von Anke L Stuurman und 15 weiteren Autor:innen. Beteiligte Einrichtung: P95 Epidemiology and Pharmacovigilance, Leuven, Belgium. Hauptthemen laut MEDLINE: COVID-19, Influenza Vaccines, Influenza, Human. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innovative Medicines Initiative.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Development of Robust and Innovative Vaccine Effectiveness (DRIVE) was a European public–private partnership (PPP) that aimed to provide annual, brand-specific estimates of influenza vaccine effectiveness (IVE) for regulatory and public health purposes. DRIVE was launched in 2017 under the umbrella of the Innovative Medicines Initiative (IMI) and conducted IVE studies from its pilot season in 2017–2018 to its final season in 2021–2022.

Methods

In 2021–2022, DRIVE conducted four primary care-based test-negative design (TND) studies (Austria, Italy, Iceland, and England; involving >1,000 general practitioners), nine hospital-based TND studies (France, Iceland, Italy, Romania, and Spain, for a total of 21 hospitals), and one population-based cohort study in Finland. In the TND studies, patients with influenza-like illness (primary care) or severe acute respiratory infection (hospital) were enrolled, and laboratory tested for influenza using RT-PCR. Study contributor-specific IVE was calculated using logistic regression, adjusting for age, sex, and calendar time, and pooled by meta-analysis.

Results

In 2021–2022, pooled confounder-adjusted influenza vaccine effectiveness (IVE) estimates against laboratory-confirmed influenza (LCI) overall and per type and subtype/lineage was produced, albeit with wide confidence intervals (CI). The limited circulation of influenza in Europe did not allow the network to reach the optimal sample size to produce precise IVE estimates for all the brands included. The most significant IVE estimates were 76% (95% CI 23%−93%) for any vaccine and 81% (22%−95%) for Vaxigrip Tetra in adults ≥65 years old and 64% (25%−83%) for Fluenz Tetra in children (TND primary care setting), 85% (12%−97%) for any vaccine in adults 18–64 years (TND hospital setting), and 38% (1%−62%) in children 6 months−6 years (population-based cohort, mixed setting).

Discussion

Over five seasons, DRIVE collected data on >35,000 patients, more than 60 variables, and 13 influenza vaccines. DRIVE demonstrated that estimating brand-specific IVE across Europe is possible, but achieving sufficient sample size to obtain precise estimates for all relevant stratifications remains a challenge. Finally, DRIVE's network of study contributors and lessons learned have greatly contributed to the development of the COVID-19 vaccine effectiveness platform COVIDRIVE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Influenza VaccinesInfluenza, HumanAdultAgedChildHumansCohort StudiesCOVID-19 VaccinesEuropeSeasonsVaccine EfficacyMaleFemaleAdolescentYoung AdultMiddle Aged

Stichwörter der Autor:innen

Europeinfluenzainfluenza vaccinespost authorizationreal-world evidencetest-negative designvaccine effectiveness

Substanzen

COVID-19 VaccinesInfluenza Vaccines

Autor:innen und Institutionen

  • P95 Epidemiology and Pharmacovigilance, Leuven, Belgium.
  • Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (Fisabio), Valencia, Spain.
  • Biomedical Research Consortium in Epidemiology and Public Health (CIBER-ESP), Instituto de Salud Carlos III, Madrid, Spain.
  • Inserm CIC 1417, Assistance Publique Hopitaux de Paris (APHP), CIC Cochin-Pasteur, Paris, France.
  • UFC Epidemiologia, Dipartimento di Prevenzione, Azienda USL Toscana Centro, Firenze, Italy.
  • Department of Health Security, Finnish Institute for Health and Welfare, Helsinki, Finland.

Förderung

  • Innovative Medicines Initiative

Zitieren

APA

Stuurman, A. L., Carmona, A., Biccler, J., Descamps, A., Levi, M., Baum, U., Mira-Iglesias, A., Bellino, S., Hoang, U., de Lusignan, S., Bonaiuti, R., Lina, B., Rizzo, C., Nohynek, H., Díez-Domingo, J., & DRIVE Study Contributors (2023). Brand-specific estimates of influenza vaccine effectiveness for the 2021–2022 season in Europe: results from the DRIVE multi-stakeholder study platform. Frontiers in Public Health. https://doi.org/10.3389/fpubh.2023.1195409

Vancouver

Stuurman AL, Carmona A, Biccler J, Descamps A, Levi M, Baum U, et al. Brand-specific estimates of influenza vaccine effectiveness for the 2021–2022 season in Europe: results from the DRIVE multi-stakeholder study platform. Frontiers in Public Health. 2023. doi:10.3389/fpubh.2023.1195409

BibTeX
@article{Stuurman2023,
  author = {Stuurman, Anke L and Carmona, Antonio and Biccler, Jorne and Descamps, Alexandre and Levi, Miriam and Baum, Ulrike and Mira-Iglesias, Ainara and Bellino, Stefania and Hoang, Uy and de Lusignan, Simon and Bonaiuti, Roberto and Lina, Bruno and Rizzo, Caterina and Nohynek, Hanna and Díez-Domingo, Javier and DRIVE Study Contributors, DRIVE Study Contributors},
  title = {Brand-specific estimates of influenza vaccine effectiveness for the 2021–2022 season in Europe: results from the DRIVE multi-stakeholder study platform},
  journal = {Frontiers in Public Health},
  year = {2023},
  doi = {10.3389/fpubh.2023.1195409}
}
Kostenlos starten →